Generation Bio Co. (GBIO)
NASDAQ$0.48
Market Cap
$32.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
238 of 924
Rank in Industry
136 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GBIO Insider Trading Activity
GBIO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $203,209 | 2 | 67 |
Sells | $18,410 | 1 | 33 |
Related Transactions
| Quinn Anthony G. | director | 2 | $203,209 | 0 | $0 | $203,209 |
| Paone Antoinette | CHIEF OPERATING OFFICER | 0 | $0 | 1 | $18,410 | $-18,410 |
About Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Generation Bio Co.
Over the last 12 months, insiders at Generation Bio Co. have bought $203,209 and sold $18,410 worth of Generation Bio Co. stock.
On average, over the past 5 years, insiders at Generation Bio Co. have bought $34.8M and sold $14.74M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Quinn Anthony G. (director) — $203,209.
The last purchase of 85,000 shares for transaction amount of $82,450 was made by Quinn Anthony G. (director) on 2025‑01‑13.
List of Insider Buy and Sell Transactions, Generation Bio Co.
| 2025-01-13 | Quinn Anthony G. | director | 85,000 0.1322% | $0.97 | $82,450 | -25.71% | ||
| 2025-01-10 | Quinn Anthony G. | director | 125,791 0.1948% | $0.96 | $120,759 | -25.78% | ||
| 2024-07-01 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 6,719 0.0099% | $2.74 | $18,410 | -15.37% | |
| 2024-01-02 | Sale | Samayoa Phillip | CHIEF STRATEGY OFFICER | 2,445 0.0032% | $1.62 | $3,961 | +34.14% | |
| 2024-01-02 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 2,445 0.0032% | $1.62 | $3,961 | +34.14% | |
| 2023-12-08 | Appelhans Dannielle | director | 8,000 0.0127% | $1.79 | $14,339 | +46.49% | ||
| 2023-12-04 | Rowland Charles A Jr | director | 150,000 0.2255% | $1.50 | $225,000 | +65.23% | ||
| 2023-12-04 | Appelhans Dannielle | director | 12,000 0.018% | $1.50 | $18,000 | +65.23% | ||
| 2023-12-01 | Rowland Charles A Jr | director | 192,960 0.2723% | $1.31 | $252,778 | +80.22% | ||
| 2023-12-01 | Nicholson Donald William | director | 100,000 0.1551% | $1.44 | $144,000 | +80.22% | ||
| 2023-12-01 | Quinn Anthony G. | director | 88,495 0.1344% | $1.41 | $124,778 | +80.22% | ||
| 2023-08-23 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 3,116 0.0046% | $4.93 | $15,362 | -44.22% | |
| 2023-07-03 | Sale | Samayoa Phillip | CHIEF STRATEGY OFFICER | 3,116 0.0054% | $5.29 | $16,484 | -41.19% | |
| 2023-04-25 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 2,914 0.0049% | $4.61 | $13,434 | -27.77% | |
| 2023-01-26 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 2,695 0.0044% | $5.56 | $14,984 | -26.23% | |
| 2023-01-10 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 1,865 0.003% | $4.57 | $8,523 | -8.80% | |
| 2023-01-09 | Sale | Samayoa Phillip | CHIEF STRATEGY OFFICER | 1,865 0.0035% | $5.11 | $9,530 | -6.05% | |
| 2022-10-27 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 2,914 0.0051% | $5.03 | $14,657 | -5.45% | |
| 2022-09-29 | Sale | Paone Antoinette | CHIEF OPERATING OFFICER | 2,828 0.0049% | $5.24 | $14,819 | -5.30% | |
| 2022-03-09 | Nicholson Donald William | 8,126 0.0137% | $4.71 | $38,273 | +14.72% |
Total: 96
*Gray background shows transactions not older than one year
Insider Historical Profitability
47.16%
| Quinn Anthony G. | director | 299286 0.4481% | $143,657.28 | 3 | 0 | +80.22% |
| Invus Public Equities, L.P. | 10 percent owner | 2814191 4.2133% | $1.35M | 1 | 0 | +47.36% |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10 percent owner | 2112546 3.1628% | $1.01M | 1 | 0 | +47.36% |
| Seybold William | 10 percent owner | 1918819 2.8728% | $921,033.12 | 1 | 0 | +47.36% |
| Zone Healthcare Holdings, LLC | 10 percent owner | 1918819 2.8728% | $921,033.12 | 1 | 0 | +47.36% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$14,315,062 | 61 | -6.21% | $32.26M | |
$22,186,116 | 57 | -43.73% | $36.64M | |
$53,490,060 | 55 | 19.35% | $29.82M | |
$23,895,365 | 34 | -37.28% | $36.88M | |
$1,295,471 | 17 | 21.79% | $25.28M |
GBIO Institutional Investors: Active Positions
| Increased Positions | 40 | +48.19% | 4M | +7.28% |
| Decreased Positions | 31 | -37.35% | 5M | -9.81% |
| New Positions | 16 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 4M | Sold Out |
| Total Postitions | 92 | +10.84% | 54M | -2.53% |
GBIO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Price T Rowe Associates Inc /Md/ | $5,382.00 | 13.85% | 9.28M | -72,531 | -0.78% | 2024-12-31 |
| Atlas Venture Life Science Advisors, Llc | $4,802.00 | 12.36% | 8.28M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $2,683.00 | 6.91% | 4.63M | -694,221 | -13.05% | 2024-12-31 |
| Blackrock, Inc. | $2,006.00 | 5.16% | 3.46M | +43,067 | +1.26% | 2024-12-31 |
| Bank Of America Corp /De/ | $1,739.00 | 4.47% | 3M | +14,647 | +0.49% | 2024-12-31 |
| Siren, L.L.C. | $1,730.00 | 4.45% | 2.98M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,532.00 | 3.94% | 2.64M | +6,274 | +0.24% | 2024-12-31 |
| Jefferies Financial Group Inc. | $1,312.00 | 3.38% | 2.26M | +2M | New | 2024-12-31 |
| Ecor1 Capital, Llc | $1,187.00 | 3.06% | 2.05M | 0 | 0% | 2024-12-31 |
| Baker Bros. Advisors Lp | $1,128.00 | 2.9% | 1.94M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.